Sunnyvale, CA 10/28/09—Symyx Technologies has announced the restructuring of its High Productivity Research business (HPR), resulting in the termination of 75 employees. The company will shut down its contract development and manufacturing operations that were acquired as part of its acquisition of contract service provider Integrity Biosolution last year (see IBO 8/15/09). Consequently, it will […]
Rockville, MD 10/19/09—Life science reagent supplier OriGene Technologies has acquired Marligen Biosciences for an undisclosed amount. OriGene is a provider of assays for the Luminex xMAP platform, as well as DNA and RNA purification kits. Maligen Bioscience provides assays for the study of gene regulation and genotyping, as well as plasmid purification kits and sample […]
Liege, Belgium 10/23/09—Reagent kit company Eurogentec SA has agreed to acquire AnaSpec, a supplier of peptides synthesis, labeled peptides and antibodies, fluorescent dyes and enzyme activity assays, for an undisclosed amount. “Our combined expertise enables Eurogentec to provide innovative solutions in the fields of Genomics and Proteomics for basic research in the biotech and pharmaceutical […]
San Diego, CA and Vienna, Austria 10/27/09—EBioscience, a supplier of cell analysis reagents, has acquired Bender MedSystems GmbH for an undisclosed amount in an all-cash transaction. Bender MedSystems GmbH is a supplier of more than 1,000 immunological research reagents and research diagnostics, including the Instant ELISA technology and FlowCytomix bead-based multiplexing technology. “Bender MedSystems provides […]
Washington, DC 10/22/09—Danaher disclosed on its quarterly conference call that its Water Quality Group has acquired Brazilian company Hexis Cientifica. Hexis Cientifica distributes lab instruments and process-monitoring products, as well as manufactures chemical reagents and lab glassware.
Toronto, Canada 10/20/09—MDS shareholders have approved the sale of the company’s Analytical Technologies business to Danaher for $650 million in cash (see IBO 9/15/09). More than 99% of the common shares voted approved the sale in a special meeting held on October 20. The sale remains subject to regulatory approval.
London, England 9/22/09, London, England 10/6/09—Millbrook Scientific Instruments has placed its subsidiary that manufactures the MiniSIMS (secondary ion MS) system into administration in order to conserve cash.
Cambridge, MA 9/16/09—Helicos Biosciences has raised approximately $9.4 million through a private placement of common stock and warrants. Purchasers include four existing investors, as well Ron Lowy, Helicos’s CEO, a new investor. In early September, the company announced it is considering strategic alternatives (see IBO 9/15/09).
Washington, DC 10/5/09—Sequenom has announced in a filing with the SEC that the US Attorneys Office, FBI and the NASDAQ have each met with the company regarding the results of its independent investigation into the development of a prenatal test for Down syndrome (see IBO 9/30/09). The investigation resulted in the firing of two company […]
New Dehli, India 10/2/09—GE Healthcare has announced that its joint venture with Wipro will take over its Indian and South Asian businesses, including GE Healthcare Life Sciences. The joint venture, in which GE Healthcare holds a 51% stake, currently distributes 85% of GE Medical Systems India’s products. The transaction will add 1,200 GE employees to […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
